Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
alnylam pharmaceuticals
8
×
boston blog main
fda
8
×
life sciences
national blog main
8
×
national top stories
8
×
boston top stories
clinical trials
new york blog main
new york top stories
rna interference
san diego blog main
san diego top stories
deals
san francisco blog main
san francisco top stories
biotech
boston
hereditary transthyretin amyloidosis
patisiran
akcea therapeutics
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
inotersen
national
novartis
raleigh-durham blog main
raleigh-durham top stories
regeneron pharmaceuticals
sanofi
seattle blog main
seattle top stories
tafamidis
texas blog main
texas top stories
wisconsin blog main
What
drug
fda
alnylam
bio
gene
medicine
medicines
roundup
deal
help
patients
pharmaceuticals
protein
rna
rnai
uses
acquire
acquisitions
afternoon
ago
agreed
alnylam’s
alzheimer’s
announced
approve
approved
approves
aren’t
awaits
billion
biological
brings
cash
caught
causing
cells
ceo
cholesterol
collabs
company
Language
unset
Current search:
fda
×
" alnylam pharmaceuticals "
×
" national top stories "
×
" national blog main "
×
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
5 years ago
Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision